An investigation for investors in Otonomy Inc (NASDAQ:OTIC) shares over potential securities laws violations by Otonomy Inc was announced and NASDAQ:OTIC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com

San Diego, CA -- (SBWire) -- 06/09/2015 --An investigation on behalf of investors of Otonomy Inc (NASDAQ:OTIC) shares over potential securities laws violations by Otonomy Inc and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Otonomy Inc (NASDAQ:OTIC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Otonomy Inc (NASDAQ:OTIC) concerning whether a series of statements by Otonomy Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On May 21, 2015 Otonomy Inc (NASDAQ:OTIC) announced results from its Phase 2b trial evaluating OTO-104 in patients with unilateral Ménière's disease. Otonomy Inc said that OTO-104 demonstrated a 61% reduction from baseline in vertigo frequency in Month 3 vs. 43% for placebo with a p value of 0.067, which narrowly missed achieving statistical significance. Shares of Otonomy Inc (NASDAQ:OTIC) declined on May 29, 2015 to as low as $22.90 per share.

On June 5, 2015, NASDAQ:OTIC shares closed at $24.58 per share.

Those who purchased shares of Otonomy Inc (NASDAQ:OTIC) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com